Impact of Acetazolamide and CPAP on Cortical Activity in Obstructive Sleep Apnea Patients by Stadelmann, Katrin et al.
Impact of Acetazolamide and CPAP on Cortical Activity in
Obstructive Sleep Apnea Patients
Katrin Stadelmann1,2, Tsogyal D. Latshang3, Yvonne Nussbaumer-Ochsner3, Leila Tarokh1,4,
Silvia Ulrich3, Malcolm Kohler2,3, Konrad E. Bloch2,3, Peter Achermann1,2*
1 Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland, 2 Zurich Center for Integrative Human Physiology, University of Zurich, Zurich,
Switzerland, 3 Pulmonary Division, University Hospital Zurich, Zurich, Switzerland, 4University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University
of Bern, Bern, Switzerland
Abstract
Study Objectives: 1) To investigate the impact of acetazolamide, a drug commonly prescribed for altitude sickness, on
cortical oscillations in patients with obstructive sleep apnea syndrome (OSAS). 2) To examine alterations in the sleep EEG
after short-term discontinuation of continuous positive airway pressure (CPAP) therapy.
Design: Data from two double-blind, placebo-controlled randomized cross-over design studies were analyzed.
Setting: Polysomnographic recordings in sleep laboratory at 490 m and at moderate altitudes in the Swiss Alps: 1630 or
1860 m and 2590 m.
Patients: Study 1: 39 OSAS patients. Study 2: 41 OSAS patients.
Interventions: Study 1: OSAS patients withdrawn from treatment with CPAP. Study 2: OSAS patients treated with autoCPAP.
Treatment with acetazolamide (500–750 mg) or placebo at moderate altitudes.
Measurements and Results: An evening dose of 500 mg acetazolamide reduced slow-wave activity (SWA; approximately
10%) and increased spindle activity (approximately 10%) during non-REM sleep. In addition, alpha activity during wake after
lights out was increased. An evening dose of 250 mg did not affect these cortical oscillations. Discontinuation of CPAP
therapy revealed a reduction in SWA (5–10%) and increase in beta activity (approximately 25%).
Conclusions: The higher evening dose of 500 mg acetazolamide showed the ‘‘spectral fingerprint’’ of Benzodiazepines,
while 250 mg acetazolamide had no impact on cortical oscillations. However, both doses had beneficial effects on oxygen
saturation and sleep quality.
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Introduction
Obstructive sleep apnea syndrome (OSAS) is a highly prevalent
respiratory disorder characterized by recurrent episodes of partial
or complete collapse of the upper airways during sleep [1],
affecting 3–7% of the population [2]. An established and effective
therapy for OSAS is treatment with continuous positive airway
pressure (CPAP), which prevents obstructive apneas, stabilizes
sleep [3,4] and reduces daytime symptoms [5]. It is known that
OSAS patients show alterations in brain activity, for example a
slowing of the EEG during waking compared to healthy controls
[6,7], as well as reduced slow-wave activity (SWA), theta and
sigma activity and slowing of sleep spindles during sleep [8–11].
The efficacy of CPAP treatment is reflected in the normalization of
cortical activity after several months, as indicated by increased
SWA during non-REM sleep and absent EEG slowing during
wakefulness [6,12].
Since mountain tourism has increased during the last decades, it
is nowadays popular to spend weekends and holidays at mountain
resorts or lodges located at moderate altitudes between 1500 and
3000 m. Sleep at altitude is altered in healthy individuals. A shift
towards lighter sleep together with an increase in central apneas
has been observed at altitude [13–16]. Compared to the
obstructive apneas observed at baseline in OSAS patients, central
apneas induced by an ascent to altitude are characterized by the
intermittent absence of the drive to breathe [17] and are generated
by the brainstem respiratory center as a response to changes in
blood gas concentrations [18]. One treatment for central apneas at
altitude is acetazolamide, a carbonic anhydrase inhibitor fre-
quently used in the treatment of acute mountain sickness [19,20].
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Acetazolamide prevents central apneas at altitude through
metabolic acidosis by its diuretic effects [21]. Sleep of OSAS
patients at 490 m and at 1630 to 2590 m with and without CPAP
treatment was investigated in three previous studies [3,22,23], in
which acetazolamide was shown to reduce central apneas
compared to placebo during sojourns to moderate altitude
[3,22]. In addition, as observed in healthy subjects [24],
acetazolamide in OSAS patients reduced the apnea/hypopnea
index compared to placebo and increased oxygen saturation and
improved sleep quality (sleep efficiency, arousals, slow-wave sleep)
[3,22].
While the positive effect of acetazolamide on breathing and
sleep architecture at altitude has been investigated [19], its effect
on cortical oscillations remains unknown. Indeed, acetazolamide is
known to reduced cortical excitability and for this reason has been
used in the treatment of epilepsy [25].
A primary aim of the present study was to examine the effect of
acetazolamide on cortical activity as measured by the sleep and
wake EEG at moderate altitude in OSAS patients. We used
quantitative analysis of the sleep and wake EEG, namely spectral
analysis, to quantify the changes in cortical activity. Due to its
frequent use and beneficial effect on sleep quality, the impact of
acetazolamide on brain function is of great interest. As some
patients discontinue their CPAP therapy for short time periods for
various reasons a secondary aim of this study was to investigate
changes in cortical oscillations during non-REM sleep resulting
from short-term discontinuation of CPAP therapy in previously
CPAP-treated OSAS patients.
Materials and Methods
We analyzed data from two randomized, placebo-controlled,
double-blind crossover trials [3,22] to evaluate the effect of two
doses of acetazolamide on the non-REM sleep and wake EEG
spectra in OSAS patients with and without CPAP treatment. In
both studies patients underwent baseline recordings at 490 m and
two study nights at moderate altitudes, during which they received
acetazolamide and placebo (see Figure 1; for study protocols see
Latshang et al. [3] and Nussbaumer-Ochsner et al. [22]). The two
studies were conducted in Zurich, Switzerland (baseline) and
Davos, Switzerland (moderate altitude) according to a similar
study protocol [3,22]. Patients were studied during 2 sojourns of 3
days at moderate altitude, 2 days (one acclimatization day) at
1860 m (study 1) or 1630 m (study 2), 1 day at 2590 m (both
studies), separated by a 2-week washout period at low altitude (,
800 m). The studies are characterized by two primary methodo-
logical differences (see Figure 1): 1) Patients in study 1 [22] stopped
CPAP treatment starting 3 nights before study periods at altitude
and baseline and received no CPAP during the study (we refer to
this condition as ‘no CPAP’). On the other hand, study 2
participants were treated with autoCPAP (mask pressure 5–15 cm
H2O [3]; referred to as ‘with CPAP’). 2) The dose of
acetazolamide administered in the evening was twice as high in
study 2 [3] compared to study 1 (Nussbaumer-Ochsner et al. [22];
500 mg compared to 250 mg). In both studies, 250 mg of
acetazolamide was administered in the morning. In addition,
patients in study 2 performed an additional recording at 490 m on
the last of 4 nights of CPAP withdrawal to assess the effect of short-
term CPAP withdrawal [3].
Participants
Male and female patients with OSAS receiving long-term CPAP
treatment, living at low altitude (,800 m) participated in the
study. All participants had a prior diagnosis of OSAS based on
excessive sleepiness and an elevated obstructive apnea/hypopnea
index (AHI; .10/h) with predominant obstructive events prior to
initiation of CPAP treatment. Thirty-nine of 49 subjects in study 1
(mean age (SD): 62 (7.6) years; obstructive AHI in the range of 16/
h to 90/h at 490 m, Table S1 in File S1) and 41 of 51 subjects in
study 2 (60 (8.5) years; obstructive AHI 18/h to 94/h at 490 m,
Table S2 in File S1) were included in the present analysis. The
exclusion criteria for EEG analyses were insufficient quality of the
non-REM sleep EEG spectra due to artifacts. Details on
demographics, study designs and inclusion/exclusion criteria have
been reported previously [3,22].
Ethics Statement
Both studies were approved by the ethics committee of the
Canton of Zurich (Switzerland) and patients gave their written
informed consent. The studies were registered (clinicaltrials.gov;
ID#NCT00714740 and ID#NCT00928655).
Polysomnographic recordings
At each session, nighttime sleep was polysomnographically
recorded with Alice5 (Philips Respironics AG, Zofingen, Switzer-
land). The EEG (derivation C3A2), submental EMG, EOG and
respiratory signals consisting of calibrated inductance plethysmo-
graphy, nasal pressure swings and pulse oximetry were measured
[3,22]. The EEG was sampled at 200 Hz (high-pass filter at
0.32 Hz; low-pass filter at 100 Hz; notch filter at 50 Hz). Sleep
stages (30-s epochs) and arousals were visually scored according to
standardized criteria [17,26].
Quantitative EEG analysis
Spectral analysis was performed on consecutive 30-s epochs
(FFTW approach, Hanning window, averages of six 5-s epochs;
frequency resolution 0.2 Hz). The three lowest frequency bins
(0.2–0.6 Hz) were excluded from analysis because of their
sensitivity to low frequency artifacts. Spectral data were analyzed
up to 20 Hz.
Non-REM sleep EEG power density spectra were calculated
over the minimal common length of non-REM sleep within
individuals. REM sleep EEG spectra could not be analyzed as
subjects in study 1 (no CPAP) had insufficient amounts of REM
sleep due to frequent apneas. Average wake EEG power density
spectra were determined over all available epochs per night (i.e.
after lights out), if all five study nights included at least 20 artifact-
free 30-s epochs of waking. A wake EEG analysis was performed
for 30 (of 39 in study 1) and 33 subjects (of 41 in study 2). Artifacts
of both, sleep and wake EEG, were identified semi-automatically.
Epochs were excluded whenever power in the beta (20–40 Hz)
and delta (0.8–4.6 Hz) band exceeded a threshold based on a
moving average determined over twenty 30-s epochs [27]. A
detailed analysis of the sleep spindle peak height and frequency
was performed. Individual peaks in the spindle frequency range
(10 to 15 Hz) were determined visually and spindle peak height
was calculated as height of the individual peak minus background
activity [27,28]. Further analysis of the wake alpha peak frequency
was performed in a similar manner as the spindle peak analysis.
Statistical analysis
Effect of altitude and acetazolamide treatment. Sleep
and respiratory variables for study 1 and 2 were summarized as
medians and interquartile ranges (Table S1 and S2 in File S1).
Comparisons between measurements at altitude and baseline and
the effect of acetazolamide compared to placebo were examined
by Wilcoxon signed rank tests. To investigate the impact of
Impact of Acetazolamide on Cortical Activity
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altitude and treatment (placebo vs. acetazolamide) on the non-
REM sleep EEG spectra, a linear mixed model ANOVA with
factors Altitude [490 m, 1860 m resp. 1630 m and 2590 m],
Treatment [acetazolamide or placebo], Order of Treatment [acetazo-
lamide-placebo, placebo-acetazolamide] and their interaction was
performed per frequency bin (Figure 2 and 3).
Effect of treatment with acetazolamide compared to
placebo. Since the mixed model ANOVA with factors Altitude
and Treatment revealed an effect of treatment in study 2 (Figure 3),
we further investigated the impact of acetazolamide on the non-
REM sleep EEG in this study. Relative spectra of acetazolamide
compared to placebo at both altitudes (acetazolamide/placebo at
1630 m and acetazolamide/placebo at 2590 m) are shown in
Figure 4. Differences between conditions were investigated by bin-
wise paired t-tests. In addition, visually detected spindle peak
characteristics (frequency and height) were compared between
acetazolamide and placebo conditions by paired t-tests.
Similar to the sleep EEG analysis, wake EEG spectra of
acetazolamide and placebo conditions at both altitudes were
compared by bin-wise paired t-tests and wake alpha peak
frequencies of study 1 and 2 were compared by paired t-tests at
both altitudes (Figure 5).
As single frequency bins may reach significance by chance but
would not be clustered in a band, we considered it relevant for our
interpretation only if $5 consecutive frequency bins (a range of
1.0 Hz) showed a significant change.
Effect of short-term CPAP discontinuation. We investi-
gated the impact of short term CPAP discontinuation on the non-
REM sleep EEG at baseline and both moderate altitudes
(Figure 6). The effect of CPAP discontinuation was examined A)
at 490 m by a within subject comparison (bin-wise paired t-tests) of
the two recordings at 490 m performed in study 2; by a between
subject comparison (bin-wise unpaired t-test): B) CPAP treatment
(placebo condition at 1630 m, study 2) vs. no CPAP treatment
(placebo condition at 1860 m, study 1) and C) CPAP treatment
(placebo condition at 2590 m, study 2) vs. no CPAP treatment
(placebo condition at 2590 m, study 1). Again, only if $5
consecutive frequency bins showed a significant change were they
considered relevant.
Results
Effect of acetazolamide on non-REM sleep and
respiratory variables
Similar to the previous analysis of the full dataset [3,22],
acetazolamide reduced central apneas at altitude and increased
sleep quality, oxygen saturation (SpO2) and carbon dioxide (CO2;
Table S1 and Table S2 in File S1).
Effect of 250 mg acetazolamide on non-REM sleep EEG
spectra (Study 1, n = 39)
An evening dose of 250 mg acetazolamide did not affect the
non-REM sleep EEG spectra. On the other hand, sleep EEG
power density in the lower frequency range (0.8–11.4 Hz; Figure 2)
was reduced in an altitude-dependent manner (mixed model
ANOVA with factors Altitude, Treatment and Order of Treatment). No
interactions between Altitude and Treatment were observed.
Effect of 500 mg acetazolamide on non-REM sleep EEG
spectra (Study 2, n = 41)
Spectral analysis of the non-REM sleep EEG revealed an
altitude- and treatment-dependent reduction of power density in
the lower frequency range (0.8–11.6 Hz; Figure 3; mixed model
ANOVA with factors Altitude, Treatment and Order of Treatment).
Acetazolamide and altitude both contributed to the reduction in
Figure 1. Design of the two studies (Study 1 [16]; Study 2 [3]). The n indicates the number of participants included in the present analyses. In
both studies, patients underwent two 3-day sojourns at two moderate altitudes, once receiving acetazolamide and once receiving placebo with a 2
week washout period at baseline level (BL, 490 m). The first night at altitude (1860 m in study 1 and 1630 m in study 2) always served for
acclimatization. The order of altitude exposure of the two study nights at lower (1860 m and 1630 m) and higher altitude (2590 m) and at baseline
(BL, 490 m) were performed in a randomized cross-over design with regard to the order of altitude exposure. Patients in study 1 stopped CPAP
treatment starting 3 nights before study periods at altitude and baseline. In total 5 study nights were analyzed in study 1 and 6 in study 2.
doi:10.1371/journal.pone.0093931.g001
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Figure 2. Non-REM sleep EEG power density spectra of study 1 (no CPAP treatment [16]): Moderate altitude compared to baseline.
A) Average spectra (n = 39) at moderate altitude (1860 m and 2590 m) of the acetazolamide (250 mg in the evening) and placebo condition are
plotted relative to baseline sleep (490 m; line at 1). Frequency resolution: 0.2 Hz. B and C) F-values of the frequency bins with significant effect of
factor Treatment and Altitude of mixed model ANOVA with factors Altitude, Treatment and Order of treatment. Bins, which showed a trend, are
indicated with white bars. D) Average absolute non-REM sleep EEG power density spectra of the 5 nights.
doi:10.1371/journal.pone.0093931.g002
Figure 3. Non-REM sleep EEG power density spectra of study 2 (with CPAP treatment [3]): Moderate altitude compared to baseline.
A) Average spectra (n = 41) at moderate altitude (1630 m and 2590 m) of the acetazolamide (500 mg in the evening) and placebo condition are
plotted relative to baseline sleep (490 m; line at 1). Frequency resolution: 0.2 Hz. B and C) F-values of the frequency bins with significant effect of
factor Treatment and Altitude of mixed model ANOVA with factors Altitude, Treatment and Order of treatment. Bins, which showed a trend, are
indicated with white bars. D) Absolute non-REM sleep EEG power density spectra of the 5 nights.
doi:10.1371/journal.pone.0093931.g003
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the lower frequency range (Treatment: 1–11.8 Hz, Altitude: 0.8–
6.8 Hz and 9.6–10.8 Hz). In addition, Altitude had an effect on the
higher frequency range (14.8–20 Hz), while Treatment revealed
differences at 12.8–13.8 Hz, indicating changes in the spindle
frequency range (11–16 Hz; sigma activity). No interactions
between Altitude and Treatment were present.
Effects of acetazolamide compared to placebo
Non-REM sleep EEG spectra. Since the ANOVA revealed
an effect of treatment (evening dose of 500 mg) in study 2, we
further investigated the effect of acetazolamide by comparing EEG
spectra of acetazolamide to placebo at each altitude (e.g.
acetazolamide/placebo at 1630 m). In this way, effects that are
due to altitude are present in both, placebo and acetazolamide
condition. A direct comparison of the two should therefore reveal
the impact of acetazolamide on the EEG spectrum independent of
altitude. At both altitudes acetazolamide reduced power density in
the lower frequency range from 1 to 9.6 Hz by approximately
10% compared to placebo at the corresponding altitude (Figure 4).
Furthermore, power density at 13.2–13.4 Hz was increased by 10–
15%. This change in the spindle frequency range (sigma activity)
suggests that spindle peak characteristics may have been affected
(Figure 3D, absolute spectra). Thus, we further investigated the
effect of acetazolamide on the spindle peak frequency and height
in a subset of 34 subjects (those that showed a spindle peak in the
non-REM sleep EEG spectra; see methods). Acetazolamide
slightly reduced the frequency of the spindle peak (1630 m:
0.1 Hz, p,0.05; 2590 m: 0.2 Hz, p,0.001) and increased peak
height (1630 m: 10%, p,0.01; 2590 m: 9%, p,0.1).
Wake EEG spectra. Similar to the non-REM sleep EEG, the
wake EEG spectra (after lights off) were only affected after
administration of an evening dose of 500 mg acetazolamide (study
2; Figure 5). Irrespective of altitude power in the 3.8–5.2 Hz and
13.6–15 Hz range was increased by acetazolamide (Figure 5C and
Figure 4. Effect of acetazolamide on non-REM sleep EEG
spectra compared to placebo at 1630 m and 2590 m (Study
2). Non-REM sleep EEG power density spectra of the acetazolamide
conditions (500 mg in the evening) at moderate altitude (1630 m and
2590 m) are plotted relative to the placebo conditions at the
corresponding altitude (line at 1). Significant differences (p,0.05,
paired t-test) between acetazolamide and placebo are indicated by ‘‘n’’
for 2590 m and ‘‘m’’ for 1630 m (n= 39). Frequency resolution: 0.2 Hz.
doi:10.1371/journal.pone.0093931.g004
Figure 5. Effect of acetazolamide on wake EEG spectra during the sleep episode. In study 1 (A and B; ‘no CPAP treatment’; n = 30) 250 mg
acetazolamide were administered in the evening and in study 2 (C and D; ‘with CPAP treatment’; n = 33) 500 mg. Acetazolamide was compared to
placebo at both altitudes. ‘‘m’’ Increase in spectral power acetazolamide compared to placebo. ‘‘.’’ Decrease in spectral power acetazolamide
compared to placebo (p,0.05 paired t-test).
doi:10.1371/journal.pone.0093931.g005
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D) whereas alpha power (8.6–11.6 Hz) was reduced compared to
placebo. Since the change in the alpha range was not centered on
the alpha peak, we suspected that administration of acetazolamide
led to a shift in the alpha peak frequency. Additional analysis of
the alpha peak frequency confirmed that similar to the spindle
peak, the location of the peak was slightly shifted to lower
frequencies by administration of acetazolamide (2650 m: 0.3 Hz,
p,0.05; 1630 m: 0.2 Hz, p,0.1).
Effects short-term discontinuation of CPAP treatment
The effect of short-term CPAP discontinuation on the non-
REM sleep EEG was investigated at 490 m and both moderate
altitudes (Figure 6). Within subject comparison were only possible
at 490 m where the subjects of study 2 were recorded with and
without CPAP treatment (see methods). Abstaining from CPAP
during one night resulted in reduced power in the delta range
(0.8–4.8 Hz; approximately 5%) and increased power in the beta
range (14.6–20 Hz; approximately 25%; Figure 6).
Discussion
This is the first study examining the effect of two doses of
acetazolamide on cortical activity in OSAS patients with and
without CPAP treatment. Compared to placebo, acetazolamide
reduced non-REM sleep EEG spectral power in the lower
frequency range (1 to 9.6 Hz) and increased sleep spindle (sigma)
activity independent of altitude. In addition, acetazolamide slightly
slowed the frequency of the spindle peak in non-REM sleep EEG
spectra and the alpha peak in waking EEG spectra. Marked
changes in brain activity were also observed at baseline and both
moderate altitudes as a result of discontinued CPAP treatment.
Short-term discontinuation of CPAP treatment for a few nights
reduced delta power (0.8–4.8 Hz) and increased beta power (14.6–
20 Hz) most likely due to the occurrence of obstructive apneas.
Acetazolamide compared to placebo
Acetazolamide is a well-established and frequently used drug to
treat acute mountain sickness (AMS) [19] and associated high-
altitude periodic breathing [24]. In addition, acetazolamide is used
to treat patients suffering from central sleep apnea due to heart
failure [29]. The recommended dosage of acetazolamide is 250–
750 mg per day [30]. In the present two studies subjects received
500 mg in study 1 (250 mg in the morning and evening [22]) and
750 mg in study 2 (250 mg in the morning, 500 mg in the evening
[3]). While the dose administered in the morning was 250 mg in
both studies, the evening-dose was twice as high in study 2
compared to study 1 (500 mg vs. 250 mg). Since the half-life time
of acetazolamide is 6–9 hours [31], one can assume that the
morning-dose had minimal influence at night and the main effect
on sleep and breathing variables was due to evening doses.
Independent of the dose, acetazolamide reduced the total AHI, by
abolishing central apneas, increased SpO2 and reduced PCO2 in
both studies [3,22]. In terms of sleep architecture, waking was
reduced and percent of non-REM sleep and sleep efficiency were
increased with acetazolamide. Changes in cortical activity as
investigated by spectral analysis of the sleep and waking EEG
were, however, only observed with the evening-dose of 500 mg in
study 2.
The reduction of EEG power in the lower frequency range (1 to
9.6 Hz) and increase in spindle power after treatment with
acetazolamide is very similar to the sleep EEG changes observed
after administration of Benzodiazepines or analogs (Z-drugs) [32–
35]. Binding of Benzodiazepines to brain GABAA receptors
promotes binding of GABA and leads to hyperpolarization of the
cells. Benzodiazepines thereby reduce the excitability of neurons
[36]. The GABAA ionophore is selectively permeable to chloride
(Cl-) and bicarbonate (HCO3
-) [37]. Opening of the membrane
channel by GABA leads to a slight efflux of HCO3
- and influx of
Cl-, resulting in a more negative membrane potential [25]. Similar
to Benzodiazepines, acetazolamide might lead to an increased
efficacy of GABA-mediated inhibition. As a carbonic anhydrase
inhibitor, acetazolamide leads to renal bicarbonate excretion and
limits the HCO3
- efflux from the GABA channel [25]. We
Figure 6. Impact of CPAP treatment on non-REM sleep EEG
spectra at 490 m and at moderate altitudes. A) Data of study 1.
Non-REM sleep EEG power density spectra of 41 OSAS patients sleeping
at 490 m ‘with CPAP’ (line at 1; AHI = 6.3 [1/h]) compared to sleeping
during interrupted CPAP treatment (‘no CPAP’; AHI = 58.3 [1/h]). ‘‘m’’
p,0.05 paired t-test comparing CPAP to ‘no CPAP’. B) Non-REM sleep
EEG power density spectra of OSAS patients during ‘no CPAP’ (study 1,
1860 m placebo condition; n = 39) compared to ‘with CPAP’ (line at 1;
study 2, 1630 m placebo condition; n = 41) and C) non-REM sleep EEG
power density spectra of OSAS patients during ‘no CPAP’ (study 1,
2590 m placebo condition) compared to ‘with CPAP’ (line at 1; study 2,
2590 m placebo condition). ‘‘m’’ p,0.05 unpaired t-test ‘with CPAP’
compared to ‘no CPAP’.
doi:10.1371/journal.pone.0093931.g006
Impact of Acetazolamide on Cortical Activity
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therefore attribute the benzodiazepine-like effect (spectral ‘‘finger-
print’’) of acetazolamide on the sleep EEG to reduced excitability
of neurons due to GABAergic hyperpolarization induced by a
reduction in bicarbonate concentration. Due to their inhibiting
effect on neuronal excitability both, acetazolamide and Benzodia-
zepines, are also effective as anticonvulsants in epileptic patients
[25,36]. The mechanisms explaining how increased GABAergic
inhibition leads to the spectral ‘‘fingerprint’’ of Benzodiazepines,
however remain unknown.
Both doses of acetazolamide were, however, sufficient to reduce
the central AHI and stabilize sleep, but only the higher evening-
dose (500 mg) revealed changes in brain oscillations observed with
spectral analysis. Whether the changes in brain oscillations
observed at the higher dose are beneficial or detrimental is
unclear. On the one hand, the absence of changes to cortical
oscillations of the lower dose may be advantageous as cortical
oscillations remain unchanged. On the other hand, benzodiaze-
pines and analogs are used to improve sleep quality and the
benzodiazepine-like effect of the higher dose on cortical oscilla-
tions may positively impact sleep. Future studies should investigate
the dose-dependent effect of acetazolamide on not only cortical
oscillations but also other outcomes measures, such as behavioral
testing (e.g. daytime alertness), to reach a final conclusion about
the best dosage.
Short-term discontinuation of CPAP therapy
Treatment with CPAP improves sleep quality [3,4,38] and
reduces daytime symptoms [5,6,39]. For example slow-wave and
REM sleep duration as well as sleep efficiency are increased with
CPAP treatment and in turn the duration of stage 1 sleep as well as
the number of arousals is reduced [3,4,6,38]. In addition, daytime
sleepiness (as measured by MSLT), cognitive performance and
mood were improved after several weeks of CPAP treatment
[5,6,39]. In contrast to the aforementioned studies which
examined previously untreated patients, we measured the impact
of short-term discontinuation of CPAP treatment. We observed
that independent of altitude (490 m, 1630/1860 m and 2590 m)
non-REM sleep slow-wave activity (SWA; 0.8–4.6 Hz) was
reduced and beta activity increased, if OSAS patients discontinued
their CPAP treatment for a few days. This observation is in
agreement with the reduction in SWA and increase in beta activity
observed during epochs of stage 2 sleep containing a respiratory
disturbance in healthy subjects sleeping at moderate altitude [40].
A reduction in SWA and increase in beta activity was also
observed in untreated OSAS patients compared to healthy
controls [9]. We therefore attribute the alterations in brain
oscillations observed during a night where patients discontinued
CPAP treatment mainly to be due to respiratory disturbances and
subsequent micro arousals or EEG activation, while other factors
such as fluctuations in oxygen saturation may have only minor
effects on EEG activity.
SWA is considered a reliable indicator of sleep depth or sleep
intensity and is used to measure sleep homeostasis [41].
Suppression of SWA due to sleep disturbances, sleep restriction
or sleep deprivation leads to increased daytime sleepiness and
impaired performance [42,43]. The impact of CPAP treatment on
SWA in sleep apnea patients was investigated by Heinzer et al.
[12]. They observed an increase in mean SWA after 9 months of
CPAP treatment concurrent with a restoration of the physiologic
decay of SWA across the night. In the same study, SWA in
untreated patients was positively correlated with daytime sleepi-
ness as assessed by MSLT. Even short-term discontinuation from
CPAP treatment may therefore have adverse effects on daytime
functioning of patients suffering from OSAS.
The effect of altitude on the sleep EEG spectra of OSAS
patients
A consistent altitude-effect on the non-REM sleep EEG spectra
is in agreement with previous findings in healthy subjects [27].
Power in the lower frequency range (0.8–11.6 Hz) was reduced in
an altitude-dependent manner, independent of CPAP treatment.
These changes are further discussed in Discussion S1 in the File
S1.
Conclusions
In summary, using quantitative analysis of the EEG as a
measure of cortical oscillations, we show that acetazolamide affects
cortical oscillations during sleep and wakefulness in a dose-
dependent manner. We demonstrated that discontinuation of
CPAP treatment has immediate adverse effects on SWA, which is
known to reflect the restorative functions of sleep. Last, we
confirmed a reduction in SWA with increasing altitude in patients
suffering from OSAS as previously observed in healthy subjects.
Supporting Information
File S1. Table S1. Sleep and respiratory variables in study 1 [1].
OSAS patients withdrawn from CPAP treatment. *p,0.05,
compared to 490 m (Wilcoxon signed ranks test). {p,0.05,
compared to corresponding placebo condition at the same altitude
(Wilcoxon signed ranks test). Data are shown as medians and
interquartile ranges. AHI: Apnea/Hypopnea Index; SpO2:
Oxygen saturation; etCO2: End tidal carbon dioxide pressure;
REMS: Rapid-eye movement sleep; SWS: Slow-wave sleep; TST:
Total sleep time; TIB: Time in bed; Sleep efficiency. TST as
percentage of TIB. N=39. Table S2. Sleep and respiratory
variables in study 2 [2]. OSAS patients treated with CPAP. *p,
0.05, compared to 490 m with CPAP (Wilcoxon signed ranks).
{p,0.05, compared to corresponding placebo condition at the
same altitude (Wilcoxon signed ranks). Data are shown as medians
and interquartile ranges. AHI: Apnea/Hypopnea Index; SpO2:
Oxygen saturation; PtcCO2: Transcutaneous carbon dioxide
pressure; REMS: Rapid-eye movement sleep; SWS: Slow-wave
sleep; TST: Total sleep time; TIB: Time in bed; Sleep efficiency.
TST as percentage of TIB. N= 41. Discussion S1. Supporting
discussion. References S1. Supporting references.
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